PRISM II: An open-label study to assess the safety, tolerability, and effectiveness of dextromethorphan 20 MG/quinidine 10 MG (nuedexta®) in pseudobulbar affect (PBA) secondary to dementia, stroke, or traumatic brain injury (TBI)-early results of trial

Authors
Category Primary study
JournalAlzheimer's and Dementia
Year 2014
This article has no abstract
Epistemonikos ID: e6a4ebb93ca3d6de31b803c87c8513b15a27f207
First added on: Feb 06, 2025